(Reuters) -Pfizer has received early U.S. antitrust clearance more than a week early for its proposed $7.3 billion Metsera ...
Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A.
In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s unsolicited proposal to acquire Metsera, renewed legal ...
Investor's Business Daily on MSN
AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47%
AbbVieABBV leaned hard on Skyrizi, Rinvoq and Botox to offset continued steep declines from Humira and its aesthetics ...
Investor's Business Daily on MSN
Dexcom Stock, Down 15%, Is Haunted By Its 'Surprisingly Cautious' Outlook
Dexcom's solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook, and Dexcom stock tumbled.
Pfizer Inc. today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback